Cohort 2 – June 2018
Dr. Evan Newell, Fred Hutchinson Cancer Research Center
Dr. Newell is an emerging leader in the field of immune cell characterization with a stellar publication record. He has pioneered a technology that includes CyTOF with heavy-metal tagged antibody staining that could have major implications in understanding immunity and cancer. Dr. Newell’s research is based on innovative techniques and will yield an unprecedented in-depth characterization of epitope usage by T-cell populations in cancer and chronic infections, which can potentially lead to novel discoveries in the field of cancer immunology.
Dr. Thomas Kensler, Fred Hutchinson Cancer Research Center
Dr. Kensler is a well-published, successful investigator with expertise in carcinogenesis and chemoprevention, and an established track record of international collaborations. His research focuses on chemoprevention as an opportunity to reduce cancer risks associated with environmental exposures to carcinogenic agents that cannot be avoided. This is a significant problem since, in the United States and internationally, environmental pollution disproportionally affects individuals who live in economically disadvantaged areas where, generally, efforts to reduce exposure are more difficult and cancer burden is higher. Dr. Kensler was recently awarded the prestigious National Cancer Institute Outstanding Investigator Award for his seminal discoveries and contributions to the field of carcinogenesis and chemoprevention.
Dr. Geoffrey Hill, Fred Hutchinson Cancer Research Center
Dr. Hill is a physician-scientist, is a world leader in the field of Bone Marrow Transplantation (BMT) and Graft Versus Host Disease (GVHD) with a stellar publication record and a history of international collaborations with academic centers and industry partners. Dr. Hill’s research will focus on better understanding GVHD pathogenesis with regard to innate and cellular immunity. Dr. Hill’s successful innovation in the field of stem cell transplantation indicate a very high potential for success in his proposed research, which will greatly impact understanding and treatment of GVHD and will be highly significant for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Dr Hill’s track record of high-quality science, mentorship, innovation, and translation is exceptional.
Cohort 1 – December 2017
Dr. Heather Greenlee, Fred Hutchinson Cancer Research Center
Dr. Greenlee is a Doctor of Naturopathic Medicine (ND) with a doctorate in epidemiology. As a population scientist, her research focus is primarily on cancer survivorship with an emphasis on the issue of obesity in cancer survivors – a research topic with high significance. Her research portfolio currently includes funded studies examining a dietary intervention among Hispanic women with breast cancer and studying factors associated with cardiovascular outcomes in breast cancer survivors. Her behavioral intervention research on cancer survivorship in racial and ethnic minority populations was deemed to have high significance and high potential for translation into patient care.
Dr. Mark Headley, Fred Hutchinson Cancer Research Center
Dr. Headley’s novel research program demonstrates strong potential for high impact in understanding the biology of lung metastasis. His research program, focused on interactions between the pulmonary immune environment and burgeoning metastases to the lung, has yielded a recent first-author publication in Nature, an indication that this research focus is an important area with high significance. His work seeks to clarify the mechanisms by which myeloid immune cells variably promote or defend against cancer. The findings from which, have significant translational potential and are anticipated to guide a new generation of metastasis-targeted interventions.
Dr. James Heath, Institute for Systems Biology
Dr. James Heath has been recruited as President of the Institute for Systems Biology (ISB) after spending the past 15 years directing large National Cancer Institute funded programs as a Professor at the California Institute of Technology. He has a track-record of success in academics, teaching, administration, and entrepreneurship. His laboratory works to develop new technologies enabling novel cancer immunotherapies. His record of high-impact productivity across a broad spectrum of scientific domains relevant to cancer research is exceptional.
Dr. Lev Silberstein, Fred Hutchinson Cancer Research Center
Dr. Silberstein’s work focuses on secreted factors that regulate the behavior of normal and malignant stem cells in the bone marrow. His research program has translational implications for addressing the important clinical problems posed by bone marrow failure, myelodysplasia, and related syndromes.